Skip to content
Hair Pipeline
← Remedies and supplements

Does Viviscal work for hair loss?

The five placebo-controlled trials of Viviscal were funded by Lifes2good, the Irish company that owned the brand until it sold it to Church & Dwight in 2017. Their results range from terminal hairs more than doubling in six months in 10 women, against a slight fall in 5 on placebo, to no rise in terminal hairs in the largest, which analysed 72 women; there, shedding was lower than on placebo at three months but not significantly so at six. Three trials were registered only after they had ended, we found no registration for the other two, and we found no trial run independently of the company. The women's tablet sold in the US today also contains iron and niacin, which none of the women's trial reports lists.

Three small trials in women

Glynis Ablon, a dermatologist with a research centre in Manhattan Beach, California, led three placebo-controlled trials in women aged 21 to 75 (21 to 65 in the three-month trial) who felt their hair was thinning, which is not a diagnosis. Women with pattern hair loss were excluded, and in the later two, women with telogen effluvium too. Thick, or terminal, hairs were counted in a 4 cm² patch of scalp. In 2012, 10 women took Viviscal and 5 a placebo for six months; terminal hairs went from 271 to 610 on Viviscal and from 256 to 242 on placebo. In a 2015 trial, 17 of 20 women on Viviscal and 19 of 20 on placebo finished; terminal hairs went from 190 to 341, against 190 to 193, and their diameter rose more than on placebo. In a three-month trial of 60 women, also published in 2015, they went from 178 to 236, against 178 to 181; shedding fell more than on placebo, but hair diameter did not differ.

The largest trial

The largest trial was run in 2011 by a contract research company at two US sites and published in 2015. It enrolled 96 women aged 21 to 55 who felt their hair was thinning, 48 on Viviscal and 48 on placebo, and analysed 72. Its primary outcomes were shedding and hair diameter. Hairs shed during a wash were fewer than on placebo at three months, when shedding on placebo had risen by more than half. At six months shedding on Viviscal was still about 18% below where it started, but no longer significantly different from placebo; the authors suggest this may be a "type II statistical error", a false negative. Fine hairs were 7.4% thicker than at the start, a change the paper reports against baseline only, not against placebo. Terminal hair counts did not increase, which the authors put down at least partly to the trial's short length. Three women on Viviscal and three on placebo reported mild bloating or stomach discomfort. The study was "100% funded by Lifes2good", and one author worked for the company.

Older trials, and trials in men

A 1992 Finnish trial gave the supplement to 20 young men with pattern baldness and a fish extract to 20 others, and reported a 38% rise in non-vellus hairs against 2%; most of the 40 had used minoxidil before. Europe's guideline on pattern hair loss notes that these early studies "were not placebo controlled". A 2001 placebo-controlled trial of Hairgain, which the 2012 Viviscal trial report says was the product's original brand name, reported it effective in 60 people with hair loss of various causes; its author worked for Parexel Medstat, the company that report names with Hairgain, and we could read only the abstract. In 2016 Ablon published a six-month placebo-controlled trial of Viviscal Man in men with diagnosed male pattern hair loss. Its abstract reports significant increases in total hair count and density after six months, and fewer hairs removed in a pull test than on placebo, but not how many men took part, and we could not read the full text.

Who paid, and when the trials were registered

All five placebo-controlled trials of Viviscal were funded by Lifes2good (for the 2016 trial, according to the journal's record of its funder). Ablon led or co-wrote all five, and in 2018 published a trial of Nutrafol, another hair supplement, funded by its maker. Three of the five were registered on ClinicalTrials.gov in November 2014, after they had ended, the largest three years after; the primary outcomes registered then match the published ones. We found no registration for the 2012 and 2016 trials on ClinicalTrials.gov, the WHO registry portal or ISRCTN, so their planned outcomes cannot be checked. We found no clinical trial of Viviscal published since 2016, and none run independently of the company. The formula has also changed: the 2012 tablet listed no biotin or zinc, and the women's tablet whose US label entered the NIH database in 2025 adds iron and niacin. Church & Dwight bought the brand from Lifes2good in 2017, and its name is on that label.

What the reviews found

A 2023 systematic review in JAMA Dermatology listed Viviscal among the products whose highest-quality studies showed a "potential benefit", and said its findings should be read in the context of each study's design. A 2026 network meta-analysis included one Viviscal trial, the 2016 trial in men; it did not list Viviscal among the supplements that significantly improved hair density or terminal hair density compared with placebo, and ranked it seventh of nine on hair density. A 2026 meta-analysis of commercial supplements included three Viviscal trials, the 1992 comparison with fish extract among them. It found no significant difference from placebo in total hair count across the three trials it pooled for that outcome, one of them the 2016 Viviscal trial in men, and concluded that "more rigorous, independent research is needed".

What it contains, safety and France

Per the NIH label database, two tablets a day of the US women's Viviscal supply 22 mg of zinc, 20 mg of iron, 240 micrograms of biotin and 900 mg of a marine complex of collagen and oyster extract. Europe's food safety authority sets the adult upper limit for zinc at 25 mg a day from all sources and a safe intake for iron at 40 mg; the American Academy of Dermatology advises iron, zinc or biotin only when a blood test shows a deficiency. The label warns that the tablets contain shark and molluscs, are not for pregnant or breastfeeding women, and that iron overdose is a leading cause of fatal poisoning in children under 6. In France, Church & Dwight declared women's and men's Viviscal as food supplements in 2019. No EU-authorised health claim about hair mentions growth.

Related questions

Sources

  1. A Double-blind, Placebo-controlled Study Evaluating the Efficacy of an Oral Supplement in Women with Self-perceived Thinning Hair · Journal of Clinical and Aesthetic Dermatology, 2012 · PMID 23198010
  2. A Randomized, Double-blind, Placebo-controlled, Multi-center, Extension Trial Evaluating the Efficacy of a New Oral Supplement in Women with Self-perceived Thinning Hair · Journal of Clinical and Aesthetic Dermatology, 2015 · PMID 26705444
  3. Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair (NCT02302053) · ClinicalTrials.gov, 2014
  4. A 3-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Ability of an Extra-Strength Marine Protein Supplement to Promote Hair Growth and Decrease Shedding in Women with Self-Perceived Thinning Hair · Dermatology Research and Practice, 2015 · PMID 25883641
  5. Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair (NCT02297360) · ClinicalTrials.gov, 2014
  6. A Marine Protein-based Dietary Supplement for Subclinical Hair Thinning/Loss: Results of a Multisite, Double-blind, Placebo-controlled Clinical Trial · International Journal of Trichology, 2015 · PMID 26903744
  7. To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair (NCT02288858) · ClinicalTrials.gov, 2014
  8. A comparative study of a new food supplement, ViviScal, with fish extract for the treatment of hereditary androgenic alopecia in young males · Journal of International Medical Research, 1992 · PMID 1286738
  9. Efficacy and Tolerability of Hairgain® in Individuals with Hair Loss: A Placebo-Controlled, Double-Blind Study · Journal of International Medical Research, 2001 · PMID 11277343
  10. A 6-month, randomized, double-blind, placebo-controlled study evaluating the ability of a marine complex supplement to promote hair growth in men with thinning hair · Journal of Cosmetic Dermatology, 2016 · PMID 27506633
  11. S3 - European Dermatology Forum Guideline for the Treatment of Androgenetic Alopecia in Women and in Men · European Dermatology Forum, 2017
  12. A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair · Journal of Drugs in Dermatology, 2018 · PMID 29742189
  13. Nutrafol Men · NIH Dietary Supplement Label Database, 2025
  14. Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss: A Systematic Review · JAMA Dermatology, 2023 · PMID 36449274
  15. Effects of dietary supplements on androgenetic alopecia: a systematic review and network meta-analysis · Frontiers in Nutrition, 2026 · PMID 41561175
  16. Evaluating the Effectiveness of Commercial Oral Supplements for Hair Growth: A Systematic Review and Meta-Analysis · Journal of Cosmetic Dermatology, 2026 · PMID 41954038
  17. Viviscal Hair Growth Supplement · NIH Dietary Supplement Label Database, 2025
  18. Overview on Tolerable Upper Intake Levels as derived by the Scientific Committee on Food (SCF) and the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) · European Food Safety Authority, 2025
  19. Hair loss: Diagnosis and treatment · American Academy of Dermatology, 2022
  20. Church & Dwight buys Viviscal in €150m deal · Cosmetics Business, 2017
  21. Déclarations de compléments alimentaires · Ministère de l'Agriculture, de l'agro-alimentaire et de la souveraineté alimentaire (data.gouv.fr), 2026
  22. Commission Regulation (EU) No 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods, other than those referring to the reduction of disease risk and to children’s development and health · European Commission, 2012

Checked against its sources on 2026-11-01, by us, not by a doctor. A research register, not medical advice: talk to a dermatologist about your own case. See why we're not doctors.